EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeting sirtuins for cancer therapy: epigenetics modifications and beyond

Hui Shen, Xinyi Qi, Yue Hu, Yi Wang, Jin Zhang, Zhongyu Liu, Zheng Qin

Theranostics · 2024 · 14 (17) · 6726-6767

DOI: 10.7150/thno.100667 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Theranostics, 2024. Verfasst von Hui Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Department of Outpatient, The First Hospital of China Medical University, Shenyang 110001, Chin…. Hauptthemen laut MEDLINE: Sirtuins, Neoplasms, Epigenesis, Genetic. Die Arbeit wurde bisher 103-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sirtuins (SIRTs) are well-known as nicotinic adenine dinucleotide+(NAD+)-dependent histone deacetylases, which are important epigenetic enzymes consisting of seven family members (SIRT1-7). Of note, SIRT1 and SIRT2 are distributed in the nucleus and cytoplasm, while SIRT3, SIRT4 and SIRT5 are localized in the mitochondria. SIRT6 and SIRT7 are distributed in the nucleus. SIRTs catalyze the deacetylation of various substrate proteins, thereby modulating numerous biological processes, including transcription, DNA repair and genome stability, metabolism, and signal transduction. Notably, accumulating evidence has recently underscored the multi-faceted roles of SIRTs in both the suppression and progression of various types of human cancers. Crucially, SIRTs have been emerging as promising therapeutic targets for cancer therapy. Thus, in this review, we not only present an overview of the molecular structure and function of SIRTs, but elucidate their intricate associations with oncogenesis. Additionally, we discuss the current landscape of small-molecule activators and inhibitors targeting SIRTs in the contexts of cancer and further elaborate their combination therapies, especially highlighting their prospective utility for future cancer drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirtuinsNeoplasmsEpigenesis, GeneticHumansAnimalsAntineoplastic AgentsMolecular Targeted TherapySignal Transduction

Stichwörter der Autor:innen

Cancer therapyEpigenetics modificationSirtuin (SIRT)Small-molecule activatorSmall-molecule inhibitor

Substanzen

SirtuinsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Department of Outpatient, The First Hospital of China Medical University, Shenyang 110001, China.
  • Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
  • School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen 518060, China.
  • No. 989 Hospital of Joint Logistic Support Force of PLA, Luoyang 471031, China.

Zitieren

APA

Shen, H., Qi, X., Hu, Y., Wang, Y., Zhang, J., Liu, Z., & Qin, Z. (2024). Targeting sirtuins for cancer therapy: epigenetics modifications and beyond. Theranostics, 14(17), 6726-6767. https://doi.org/10.7150/thno.100667

Vancouver

Shen H, Qi X, Hu Y, Wang Y, Zhang J, Liu Z, et al. Targeting sirtuins for cancer therapy: epigenetics modifications and beyond. Theranostics. 2024;14(17):6726-6767. doi:10.7150/thno.100667

BibTeX
@article{Shen2024,
  author = {Shen, Hui and Qi, Xinyi and Hu, Yue and Wang, Yi and Zhang, Jin and Liu, Zhongyu and Qin, Zheng},
  title = {Targeting sirtuins for cancer therapy: epigenetics modifications and beyond},
  journal = {Theranostics},
  year = {2024},
  volume = {14},
  number = {17},
  pages = {6726--6767},
  doi = {10.7150/thno.100667}
}
Kostenlos starten →